메뉴 건너뛰기




Volumn 2, Issue 7, 2006, Pages 358-364

Rational design of inhibitors that bind to inactive kinase conformations

Author keywords

[No Author keywords available]

Indexed keywords

DORAMAPIMOD; IMATINIB; SORAFENIB;

EID: 33745298429     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio799     Document Type: Review
Times cited : (964)

References (36)
  • 2
    • 0032227735 scopus 로고    scopus 로고
    • The role of tyrosine phosphorylation in cell growth and disease
    • Hunter, T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect. 94, 81-119 (1998).
    • (1998) Harvey Lect. , vol.94 , pp. 81-119
    • Hunter, T.1
  • 3
    • 0036527429 scopus 로고    scopus 로고
    • Protein kinases - The major drug targets of the twenty-first century?
    • Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
    • (2002) Nat. Rev. Drug Discov. , vol.1 , pp. 309-315
    • Cohen, P.1
  • 4
    • 4944261336 scopus 로고    scopus 로고
    • Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors
    • Mol, C.D., Fabbro, D. & Hosfield, D.J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Devel. 7, 639-648 (2004).
    • (2004) Curr. Opin. Drug Discov. Devel. , vol.7 , pp. 639-648
    • Mol, C.D.1    Fabbro, D.2    Hosfield, D.J.3
  • 5
    • 0034665713 scopus 로고    scopus 로고
    • Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
    • Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
    • (2000) Science , vol.289 , pp. 1938-1942
    • Schindler, T.1
  • 6
    • 18344395134 scopus 로고    scopus 로고
    • Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
    • Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9, 268-272 (2002).
    • (2002) Nat. Struct. Biol. , vol.9 , pp. 268-272
    • Pargellis, C.1
  • 7
    • 12144289677 scopus 로고    scopus 로고
    • Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    • Wan, P.T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
    • (2004) Cell , vol.116 , pp. 855-867
    • Wan, P.T.1
  • 8
    • 12144290647 scopus 로고    scopus 로고
    • Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
    • Manley, P.W. et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697, 17-27 (2004).
    • (2004) Biochim. Biophys. Acta , vol.1697 , pp. 17-27
    • Manley, P.W.1
  • 9
    • 19944434344 scopus 로고    scopus 로고
    • Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation
    • Gill, A.L. et al. Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48, 414-426 (2005).
    • (2005) J. Med. Chem. , vol.48 , pp. 414-426
    • Gill, A.L.1
  • 10
    • 5444244504 scopus 로고    scopus 로고
    • Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase
    • Cumming, J.G. et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 14, 5389-5394 (2004).
    • (2004) Bioorg. Med. Chem. Lett. , vol.14 , pp. 5389-5394
    • Cumming, J.G.1
  • 11
    • 31344438721 scopus 로고    scopus 로고
    • SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors
    • Heron, N.M. et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16, 1320-1323 (2006).
    • (2006) Bioorg. Med. Chem. Lett. , vol.16 , pp. 1320-1323
    • Heron, N.M.1
  • 12
    • 0033026444 scopus 로고    scopus 로고
    • Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
    • Traxler, P. & Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82, 195-206 (1999).
    • (1999) Pharmacol. Ther. , vol.82 , pp. 195-206
    • Traxler, P.1    Furet, P.2
  • 13
    • 32344437258 scopus 로고    scopus 로고
    • Discovery of novel and potent thiazoloquinazolines as selective Aurora a and B kinase inhibitors
    • Jung, F.H. et al. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J. Med. Chem. 49, 955-970 (2006).
    • (2006) J. Med. Chem. , vol.49 , pp. 955-970
    • Jung, F.H.1
  • 14
    • 24944543833 scopus 로고    scopus 로고
    • Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors
    • Dai, Y. et al. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 48, 6066-6083 (2005).
    • (2005) J. Med. Chem. , vol.48 , pp. 6066-6083
    • Dai, Y.1
  • 15
    • 0032563315 scopus 로고    scopus 로고
    • Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
    • Gray, N.S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
    • (1998) Science , vol.281 , pp. 533-538
    • Gray, N.S.1
  • 16
    • 0033200390 scopus 로고    scopus 로고
    • Structural basis for selective inhibition of Src family kinases by PP1
    • Liu, Y. et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671-678 (1999).
    • (1999) Chem. Biol. , vol.6 , pp. 671-678
    • Liu, Y.1
  • 17
    • 0032530336 scopus 로고    scopus 로고
    • Structural basis of inhibitor selectivity in MAP kinases
    • Wang, Z. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128 (1998).
    • (1998) Structure , vol.6 , pp. 1117-1128
    • Wang, Z.1
  • 18
    • 12644277392 scopus 로고    scopus 로고
    • The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
    • Wilson, K.P. et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423-431 (1997).
    • (1997) Chem. Biol. , vol.4 , pp. 423-431
    • Wilson, K.P.1
  • 19
    • 0028582185 scopus 로고
    • Crystal structure of the tyrosine kinase domain of the human insulin receptor
    • Hubbard, S.R., Wei, L., Ellis, L. & Hendrickson, W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754 (1994).
    • (1994) Nature , vol.372 , pp. 746-754
    • Hubbard, S.R.1    Wei, L.2    Ellis, L.3    Hendrickson, W.A.4
  • 20
    • 0036682301 scopus 로고    scopus 로고
    • Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
    • Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
    • (2002) Cancer Res. , vol.62 , pp. 4236-4243
    • Nagar, B.1
  • 21
    • 0036769168 scopus 로고    scopus 로고
    • Imatinib: A selective tyrosine kinase inhibitor
    • Manley, P.W. et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38 (suppl. 5), S19-S27 (2002).
    • (2002) Eur. J. Cancer , vol.38 , Issue.5 SUPPL.
    • Manley, P.W.1
  • 22
    • 0037019275 scopus 로고    scopus 로고
    • Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate
    • Regan, J. et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45, 2994-3008 (2002).
    • (2002) J. Med. Chem. , vol.45 , pp. 2994-3008
    • Regan, J.1
  • 23
    • 0036401042 scopus 로고    scopus 로고
    • Design and discovery of small molecules targeting raf-1 kinase
    • Lowinger, T.B., Riedl, B., Dumas, J. & Smith, R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 8, 2269-2278 (2002).
    • (2002) Curr. Pharm. Des. , vol.8 , pp. 2269-2278
    • Lowinger, T.B.1    Riedl, B.2    Dumas, J.3    Smith, R.A.4
  • 24
    • 19944429284 scopus 로고    scopus 로고
    • A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
    • Atwell, S. et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827-55832 (2004).
    • (2004) J. Biol. Chem. , vol.279 , pp. 55827-55832
    • Atwell, S.1
  • 25
    • 4644289313 scopus 로고    scopus 로고
    • A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
    • Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
    • (2004) Cancer Res. , vol.64 , pp. 6652-6659
    • Wood, E.R.1
  • 26
    • 0034642482 scopus 로고    scopus 로고
    • Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
    • Shewchuk, L. et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4- anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43, 133-138 (2000).
    • (2000) J. Med. Chem. , vol.43 , pp. 133-138
    • Shewchuk, L.1
  • 27
    • 85029168478 scopus 로고    scopus 로고
    • Preparation of pyrazolo[3,4-d]pyrimidine derivatives for treating diseases associated with inappropriate angiogenesis. World patent application WO2003029209 (2003)
    • Adams, J.L., Kasparec, J., Silva, D. & Yuan, C.C.K. Preparation of pyrazolo[3,4-d]pyrimidine derivatives for treating diseases associated with inappropriate angiogenesis. World patent application WO2003029209 (2003).
    • Adams, J.L.1    Kasparec, J.2    Silva, D.3    Yuan, C.C.K.4
  • 28
    • 20144375600 scopus 로고    scopus 로고
    • Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: Synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-(4-(4-quinolyloxy)phenyl)ureas
    • Kubo, K. et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-(4-(4-quinolyloxy)phenyl)ureas. J. Med. Chem. 48, 1359-1366 (2005).
    • (2005) J. Med. Chem. , vol.48 , pp. 1359-1366
    • Kubo, K.1
  • 29
    • 85029155343 scopus 로고    scopus 로고
    • Preparation of heteroaryl-substituted diarylureas as tyrosine kinase inhibitors. World patent application WO2005019192 (2005)
    • Hoelzemann, G. et al. Preparation of heteroaryl-substituted diarylureas as tyrosine kinase inhibitors. World patent application WO2005019192 (2005).
    • Hoelzemann, G.1
  • 30
    • 85029153574 scopus 로고    scopus 로고
    • Preparation of pyrimidopyrimidines as protein kinase inhibitors. World patent application WO2005011597 (2005)
    • Sim, T. et al. Preparation of pyrimidopyrimidines as protein kinase inhibitors. World patent application WO2005011597 (2005).
    • Sim, T.1
  • 31
    • 85029177746 scopus 로고    scopus 로고
    • Preparation of [1,6]naphthyridin-3-ones as protein kinase inhibitors. ç patent application WO2005034869 (2005)
    • Ding, Q. et al. Preparation of [1,6]naphthyridin-3-ones as protein kinase inhibitors. ç patent application WO2005034869 (2005).
    • Ding, Q.1
  • 32
    • 85029169583 scopus 로고    scopus 로고
    • Preparation of N-[3-(2-amino-7-oxo-7,8-dihydropteridin-6-yl)phenyl] benzamides as protein kinase inhibitors. World patent application WO2006002367 (2006)
    • Ren, P., Wang, X., Gray, N.S., Liu, Y. & Sim, T. Preparation of N-[3-(2-amino-7-oxo-7,8-dihydropteridin-6-yl)phenyl] benzamides as protein kinase inhibitors. World patent application WO2006002367 (2006).
    • Ren, P.1    Wang, X.2    Gray, N.S.3    Liu, Y.4    Sim, T.5
  • 33
    • 19744365702 scopus 로고    scopus 로고
    • A small molecule-kinase interaction map for clinical kinase inhibitors
    • Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
    • (2005) Nat. Biotechnol. , vol.23 , pp. 329-336
    • Fabian, M.A.1
  • 35
    • 29144520253 scopus 로고    scopus 로고
    • Exploiting structural principles to design cyclin-dependent kinase inhibitors
    • Noble, M. et al. Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochim. Biophys. Acta 1754, 58-64 (2005).
    • (2005) Biochim. Biophys. Acta , vol.1754 , pp. 58-64
    • Noble, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.